Related Experiment Video

Updated: May 26, 2025

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics
06:00

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics

Published on: May 14, 2016

11.0K

A clinical drug candidate that triggers non-apoptotic cancer cell death

Scott Dixon1, Logan Leak1, Ziwei Wang2

  • 1Stanford University.

Research Square
|February 24, 2025
PubMed

Insights

Tegavivint, a cancer drug candidate, triggers a novel form of non-apoptotic cell death in cancer cells. This process relies on the lipid metabolic enzyme trans-2,3-enoyl-CoA reductase (TECR) to synthesize palmitate.

Area of Science:

  • Biochemistry
  • Oncology
  • Cell Biology

Background:

  • Non-apoptotic cell death pathways are crucial for cancer therapy.
  • Novel mechanisms of cell death induction are needed to overcome drug resistance.

Purpose of the Study:

  • To investigate the mechanism of cell death induced by tegavivint.
  • To identify the molecular players involved in tegavivint-mediated cell death.

Main Methods:

  • Cell viability assays
  • Western blotting
  • Lipidomic analysis
  • Enzyme activity assays

Main Results:

  • Tegavivint induces a unique form of non-apoptotic cell death in sarcomas and other cancer cells.
  • This cell death mechanism is dependent on the lipid metabolic enzyme trans-2,3-enoyl-CoA reductase (TECR).
  • TECR activity leads to the synthesis of palmitate, a saturated long-chain fatty acid, promoting cell death.

Conclusions:

  • Tegavivint activates a novel, lipid-dependent non-apoptotic cell death pathway.
  • TECR plays a critical role in mediating this cell death.
  • This pathway represents a potential therapeutic strategy for cancers, particularly those resistant to conventional treatments.
Keywords:
TECRcancernecrosispalmitate

More Related Videos

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo09:19

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo

Published on: February 6, 2015

8.4K
Enhancement of Apoptotic and Autophagic Induction by a Novel Synthetic C-1 Analogue of 7-deoxypancratistatin in Human Breast Adenocarcinoma and Neuroblastoma Cells with Tamoxifen19:44

Enhancement of Apoptotic and Autophagic Induction by a Novel Synthetic C-1 Analogue of 7-deoxypancratistatin in Human Breast Adenocarcinoma and Neuroblastoma Cells with Tamoxifen

Published on: May 30, 2012

18.7K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.4K
The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
6.0K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.8K
The Extrinsic Apoptotic Pathway01:17

The Extrinsic Apoptotic Pathway

The extrinsic apoptotic pathway is initiated when extracellular death-inducing signals, such as specific cytokines, activate the death receptors expressed on the cell surface. The immune cells involved in this pathway are natural killer cells (NK cells) and cytotoxic T-lymphocytes. NK cells are critical in innate immune response, while cytotoxic T-lymphocytes are associated with adaptive immune response. These cells recognize specific receptors expressed on the altered cells and activate...
5.9K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.6K